Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive entities : Kering save search
Apellis to Present Positive Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G at Kidney Week
Published: 2023-10-17 (Crawled : 11:00) - globenewswire.com
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: -1.4%
H: 2.43%
C: 0.02%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: -2.01%
H: 2.36%
C: 1.96%
APLS G | $47.68 0.32% 0.31% 690K
|
Health Technology
|
| O: 0.66%
H: 1.2%
C: -3.55%
kidney positive week results
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
Published: 2023-04-17 (Crawled : 11:00) - globenewswire.com
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: 0.05%
H: 1.69%
C: -1.81%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: -2.08%
H: 0.03%
C: -0.19%
PCVX | $61.595 1.26% 1.24% 620K
|
Health Technology
|
| O: 15.18%
H: 6.42%
C: 0.71%
STRO | $3.77 3.86% 3.71% 520K
|
Health Technology
|
| O: 0.68%
H: 8.13%
C: 5.64%
vax-24 pneumococcal vaccine positive study phase 2
Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Against High Blood Pressure
Published: 2023-01-30 (Crawled : 17:00) - biospace.com/
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: 1.84%
H: 0.26%
C: -1.13%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: 0.25%
H: 1.36%
C: 0.69%
blood positive results
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
Published: 2022-10-24 (Crawled : 11:00) - biospace.com/
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: 0.55%
H: 3.41%
C: -0.9%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: -0.01%
H: 0.83%
C: -0.01%
PCVX | $61.595 1.26% 1.24% 620K
|
Health Technology
|
| O: 70.8%
H: 2.7%
C: -6.12%
STRO | $3.77 3.86% 3.71% 520K
|
Health Technology
|
| O: 0.71%
H: 14.96%
C: 13.91%
candidate disease topline vaccine positive study pneumococcal
Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs
Published: 2022-08-04 (Crawled : 17:00) - biospace.com/
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: 0.0%
H: 5.96%
C: 2.52%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: 0.04%
H: 1.21%
C: 0.78%
PCVX | $61.595 1.26% 1.24% 620K
|
Health Technology
|
| O: 1.43%
H: 3.54%
C: 3.14%
STRO | $3.77 3.86% 3.71% 520K
|
Health Technology
|
| O: 1.68%
H: 1.28%
C: 0.55%
vax-24 positive
Athira Puts Positive Spin on Alzheimer’s Trial Despite Missed Endpoint
Published: 2022-06-22 (Crawled : 14:20) - biospace.com/
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: -0.6%
H: 5.96%
C: 1.4%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: -2.59%
H: 2.19%
C: 1.04%
trial alzheimer’s positive alzheimer's
Delek Logistics Partners, LP Announces Acquisition of 3Bear Energy Increasing its Prominent Position in the Permian Basin
Published: 2022-04-11 (Crawled : 13:00) - prnewswire.com
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: -2.37%
H: 3.76%
C: 0.53%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: -1.49%
H: 0.09%
C: -1.55%
DK 4 | $29.61 -0.2% 0.0% 730K
|
Energy Minerals
|
| O: -0.93%
H: 1.12%
C: -1.61%
DKL | $38.9 1.25% -0.39% 76K
|
Industrial Services
|
| O: 0.93%
H: 3.0%
C: 0.6%
acquisition energy positive
Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia
Published: 2022-03-29 (Crawled : 09:00) - biospace.com/
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: 4.54%
H: 4.11%
C: -1.36%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: 3.52%
H: 0.48%
C: -1.08%
positive results hypercholesterolemia
iOnctura Presents Positive Clinical Data At ESMO-IO Supporting Advancement of IOA-289, a Novel Autotaxin Inhibitor, Into Phase Ib Pancreatic Cancer Studies
Published: 2021-12-09 (Crawled : 08:00) - biospace.com/
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: -6.26%
H: 4.62%
C: 0.72%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: -2.24%
H: 0.01%
C: -0.69%
ioa-289 xin positive cancer pancreatic
Ayurcann Holdings Corp. Reports Third Consecutive Quarter of Positive Operating Income
Published: 2021-11-29 (Crawled : 17:00) - globenewswire.com
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: 0.14%
H: 4.98%
C: 2.88%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: 3.3%
H: 0.39%
C: 0.17%
positive
iOnctura Clinical Expansion Positions Lead PI3Kδ Inhibitor IOA-244 for Potential Registration Studies in Metastatic Uveal Melanoma
Published: 2021-11-08 (Crawled : 10:00) - biospace.com/
PPRUF | News | $358.446 37.56% 290
|
Consumer Non-Durables
|
| O: -0.16%
H: 0.52%
C: 0.28%
PPRUY | News | $36.08 -0.11% 150K
|
Manufacturing
|
| O: 1.09%
H: 0.21%
C: -0.16%
potential expansion positive
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.